SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is surging as a short-seller retracted damaging allegations, sparking strong community discussion around a potential short squeeze and a significant rebound for the stock ahead of its upcoming earnings report.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending sharply lower following the FDA's Complete Response Letter for its RGX-121 gene therapy, citing concerns with trial design and a clinical hold linked to a potential tumor in a related program. The community is fiercely debating the severe impact on the company's immediate future and the broader gene therapy sector, while some highlight the continued value of other key pipeline assets.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending after its recent earnings report presented mixed results and conservative guidance, leading to a sharp market sell-off. Community discussion centers on whether the stock is oversold and fundamentally undervalued given its profitability, or if broader fintech sector headwinds and management's cautious outlook justify the decline.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork is trending following a mixed earnings report where strong Q4 results were overshadowed by lower-than-expected Q1 guidance, leading to a significant stock decline. The community is sharply divided, debating whether the dip presents a buying opportunity or if concerns about declining active clients and AI's impact on the gig economy are valid.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean (RIG) is a hot topic following its all-stock acquisition of Valaris, as investors debate if the newly formed offshore drilling leader, poised for over $200 million in synergies, marks the start of a significant upcycle for the stock.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings Inc. is trending sharply lower after the abrupt departures of its CFO and general counsel amid an accounting review and delayed regulatory filings, prompting community discussions ranging from severe financial irregularity concerns to perceptions of an extreme, oversold market reaction.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv ($FISV) is trending as investors eagerly await its upcoming earnings report, creating a stark community divide between bulls citing undervaluation and strong fundamentals, and bears fearing another significant drop. Many are drawing parallels to recent struggles in the fintech sector and notable declines from companies like PayPal, contributing to heightened options activity and uncertainty.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is trending following a significant sell-off after it issued weaker-than-expected revenue guidance, intensifying broader market concerns that AI tools could disrupt traditional software business models. The community is divided, with many calling the drop an overreaction and a buying opportunity, while others believe AI will render such platforms obsolete.

Amentum Holdings, Inc. engages in mission-critical, technology-driven services in government and commercial markets. It operates through the Digital Solutions and Global Engineering Solutions segments. The Digital Solutions segment provides advanced digital and data-driven solutions including intelligence analytics, space system development, cybersecurity, and next generation IT. The Global Engineering Solutions segment manages large-scale environmental remediation, nuclear power solutions, platform engineering, sustainment and supply chain management. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum Holdings is trending after reporting mixed Q1 earnings with a revenue miss attributed to transient factors, while affirming strong FY26 guidance and touting a robust and growing contract backlog. Community sentiment is notably divided between short-term disappointment over stock performance and strong long-term conviction in its pivotal role within nuclear energy, defense, and space systems.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending following its Q4 earnings report and cautious Q1 revenue guidance, which, despite an EPS beat, ignited concerns about a potential "blood bath" due to an EV market slowdown and inventory. However, bullish sentiment highlights the company's strategic investments in intelligent power and sensing for AI data centers, including a new partnership with Nvidia, as key long-term growth drivers attracting dip buyers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail chatter around Cingulate picked up on Tuesday after Roth Capital Partners raised its price target to $17 from $10 and reaffirmed a ‘Buy’ rating.&nbsp;<a href="https://stocktwits.com/symbol/CING">Cingulate Inc.’s stock</a> snapped a two-day losing streak, rising 2.5% to $4.15 on Tuesday, and added another 1.6% in after-hours trading.The firm said the FDA’s acceptance of Cingulate’s application for its ADHD drug CTx-1301 signals confidence in the treatment’s safety and effectiveness for both children and adults.Roth analysts said the absence of an Advisory Committee review, an earlier-than-expected PDUFA date of May 31, 2026, and a potentially broad label across ADHD patients all strengthen the investment case for Cingulate. They also highlighted the strong approval track record of ADHD stimulants as supportive of the drug’s prospects.The FDA’s acceptance marks a major step forward for CTx-1301, which uses Cingulate’s proprietary Precision Timed Release technology to deliver once-daily, all-day symptom control. The company said Phase 3 data showed rapid onset and sustained efficacy with no serious safety issues reported.The company called the FDA acceptance a “defining milestone”, positioning Cingulate to transition from a development-stage to a commercial-stage company in 2026, pending approval. The firm said commercial preparations are already underway through partnerships with Bend Bio Sciences and Indegene to ensure manufacturing scale-up and market readiness.On Stocktwits, retail sentiment for Cingulate was ‘bullish’ amid an 820% surge in 24-hour message volume.One bullish user highlighted the advantages of Cingulate’s regulatory route, noting it follows a faster and less expensive path typically used for drugs that build on existing approvals with new delivery methods. They noted the company’s silence on social media could hint at buyout interest and said they would only part with their shares for $27.<stembedurl>https://stocktwits.com/StockGuru320/message/632269303</stembedurl>Another bullish user noted that, with the NDA now accepted, the real question for investors was the risk they were taking by not owning the stock at this stage. They added that long-term holders were feeling more confident than ever about the company’s direction.<stembedurl>https://stocktwits.com/Duke1979/message/632260917</stembedurl>Cingulate’s stock has declined 16% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cingulate’s stock (CING) has declined 16% so far in 2025. (Photo credit: Getty Images)

Cingulate Stock Snaps 2-Day Losing Streak As Roth Hikes Target On ADHD Drug Review; Retail Bets On Buyout Potential

Roth Capital said the FDA’s acceptance shows strong confidence in Cingulate’s ADHD drug, adding that its early PDUFA date and clean regulatory path make it a good investment.

Equity

Retail chatter around Cingulate spiked Tuesday after Phase 3 data confirmed that its lead candidate, CTx-1301, significantly improved ADHD symptoms in pediatric patients within five weeks of treatment.At Tuesday's close, Cingulate shares fell 4.99% to $3.62 and slipped further 1.66% to $3.56 in after-hours trading.According to the Kansas-based biotech, children who took CTx-1301 at doses of 18.75 mg, 25 mg, and 37.5 mg experienced significant reductions in their ADHD-RS-5 scores.Dr. Raul Silva, chief science officer at Cingulate, revealed the possibility of CTx-1301 becoming a primary treatment option for ADHD after demonstrating effect sizes between 0.737 and 1.185, which surpass the industry standard of 0.73 for long-duration stimulants.CEO Shane Schaffer identified the findings as a “significant value inflection point” while confirming that the company plans to file a New Drug Application (NDA) this summer.CTx-1301 uses Cingulate’s Precision Timed Release platform to provide a single daily dose, which begins working in the morning and maintains effectiveness throughout the day.After receiving FDA approval, the company plans to offer eight different dosage strengths to address the pediatric and adult ADHD markets.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 2,700% surge in 24-hour message volume.One user highlighted the forthcoming FDA submission as a key milestone and suggested that the recent decline in share price may offer a buying opportunity.&nbsp;<stembedurl>https://stocktwits.com/Duke1979/message/615297512</stembedurl>Another user was more cautious, noting that the effect size observed in the pediatric trial appeared lower than earlier projections. However, they acknowledged that sustained efficacy throughout the day could remain a key differentiator.<stembedurl>https://stocktwits.com/TheSterl/message/615215732</stembedurl>The stock has declined 29% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cingulate Retail Buzz Surges As ADHD Drug Shows Phase 3 Pediatric Efficacy

Phase 3 data showed the company’s ADHD drug, CTx-1301, significantly improved symptoms in children within five weeks. The company plans to file for FDA approval this summer.

Cingulate Inc.'s shares generated heightened retail chatter on Wednesday after receiving the FDA's pre-New Drug Application (NDA) meeting minutes for its primary asset CTx-1301 that targets ADHD with a daily stimulant treatment.Cingulate shares rose 8.7% to close at $4.25 on Tuesday but slipped 4.2% to $4.07 in after-hours trading.Following a pre-NDA meeting on April 2, the company confirmed that it will submit an NDA for CTx-1301 in the summer of 2025 based on the FDA’s feedback.&nbsp;The formulation CTx-1301 contains dexmethylphenidate and employs Cingulate’s Precision Timed Release technology to provide three doses during specific times of the day.&nbsp;The technology aims to overcome the problem of reduced effectiveness in existing stimulant treatments during the afternoon hours.The FDA minutes confirmed that the existing nonclinical safety data sufficiently support the NDA submission.The agency entered into a post-approval agreement with Cingulate to gather stability data for six intermediate dose strengths, spanning from 12.5 mg to 43.75 mg.The regulatory body recognized a scientific connection to Focalin XR, which permitted Cingulate to benefit from existing data on drug effectiveness and safety.&nbsp;The agency found the company’s integrated safety and efficacy summary approaches reasonable.One user said the stock could reach $6, citing a sharp spike to $5.16 as a signal of potential upward momentum.&nbsp;On Stocktwits, retail sentiment was ‘bullish’ amid a 1,600% surge in 24-hour message volume.<stembedurl>https://stocktwits.com/doublenickels55/message/614579894</stembedurl>Another user highlighted the absence of negative news and reaffirmed confidence in the NDA timeline, noting the company remains on track for a summer submission.<stembedurl>https://stocktwits.com/fullobullz/message/614577626</stembedurl>The stock has declined 16.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug

CTx-1301 employs its Precision Timed Release system to administer three doses of dexmethylphenidate throughout the day for managing ADHD symptoms.

<a href="https://stocktwits.com/symbol/CING">Cingulate Inc</a>. (CING) shares skyrocketed over 85% in pre-market trading on Friday, becoming the top trending stock on Stocktwits. The surge comes after the stock rallied nearly 160% on Thursday, triggered by the company's announcement of a European patent for its ADHD drug candidate, CTx-1301.This patent expands Cingulate's intellectual property protection to include up to 30 European countries, adding to its existing patents in Australia, Canada, and Israel. The company is also pursuing patents in Hong Kong, South Korea, and the United States.ADHD is a significant global health issue, affecting millions worldwide. Cingulate's focus on developing treatments for ADHD aligns with its broader strategy of utilizing its proprietary PTR technology for other therapeutic areas, such as anxiety disorders.The patent news has injected a much-needed dose of optimism into the stock, which has lost over 94% of its value this year due to several headwinds.The company reported disappointing Q2 earnings and has been grappling with financial challenges, including a significant cash burn and a history of top executive departures.Cingulate has a cash balance of just $0.4 million as of June 30, 2024. To address this, the company raised $1.6 million in July through warrant inducement and plans to seek additional funding.A regulatory filing last year warned of potential bankruptcy if financial issues persisted.<stembedurl>https://stocktwits.com/SelectiveTrader/message/583139933</stembedurl>Despite these challenges, the European patent news has reignited interest in Cingulate. However, it remains to be seen if this momentum can be sustained and if the company can successfully navigate its financial hurdles to capitalize on its drug development pipeline. &nbsp;

ADHD is a significant global health issue, affecting millions worldwide. Image via Vecteezy

Cingulate Stock Is Hottest Talk Of Retail Street After Europe Patent For ADHD Drug Candidate

Retail investors, buoyed by the news, are actively discussing the stock on Stocktwits. However, some remain cautious due to the company's troubled history and ongoing financial challenges.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

CING
Cingulate Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest CING News

CINGCingulate Inc